|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors.
|
25596284 |
2015 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.
|
24931608 |
2014 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging.
|
31132309 |
2019 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
|
18093943 |
2007 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
|
26058074 |
2015 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to cancer cells, and it was shown that mice expressing tetracycline-inducible EGFR transgenes harboring the T790M mutation develop lung tumors.
|
19096299 |
2009 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs121913279
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using GEM models, we tested whether PI3'-lipid signaling was limiting for the promotion of KRAS(G12D)-driven lung tumors by inducing the expression of KRAS(G12D) in the absence and presence of the activating PIK3CA(H1047R) mutation.
|
26567140 |
2015 |
|
rs121913369
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
|
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Moreover, Klf5 is not required for lung tumor formation in an inducible oncogenic K-Ras(G12D) mouse model of lung tumorigenesis, and non-small cell lung cancer patients expressing high levels of KLF5 (21/258) have a significantly better disease-specific survival than those with intermediate to no KLF5 expression.
|
20639455 |
2010 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Importantly, the combined inactivation of both MYC and K-ras(G12D) resulted more frequently in complete lung tumor regression.
|
18461184 |
2008 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.
|
23959381 |
2013 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids.
|
25077772 |
2014 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
|
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Using GEM models, we tested whether PI3'-lipid signaling was limiting for the promotion of KRAS(G12D)-driven lung tumors by inducing the expression of KRAS(G12D) in the absence and presence of the activating PIK3CA(H1047R) mutation.
|
26567140 |
2015 |
|
rs121913530
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We find no evidence of heterogeneity that may compromise KRAS G12C targeted therapy within sequenced lung tumors or passaged xenografts.
|
29453361 |
2018 |
|
rs1238968510
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we compared polymorphisms pertaining to MMP genes in healthy controls and lung tumor DNA, we observed a decrease in the MMP-2 (-735) polymorphism GG genotype and increases in the MMP-13 (A77G) polymorphism AG and GG genotypes (P = 0.008, P = 0.047, and P = 0.047, respectively).
|
23465389 |
2013 |
|
rs1242640031
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
|
16051643 |
2005 |
|
rs1256061
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele.
|
23619141 |
2013 |